Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病 骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
多发性骨髓瘤是一种血浆细胞癌症。
问：当你最早发现自己出现多发性骨髓瘤症状时，却失望地发现现有研究对如何治疗的决定并无多大帮助。
Q: When you first developed symptoms of multiple myeloma, you were disappointed to find that available research was not very helpful in deciding what to do.
应用推荐